Prosetta's Management

 

Vishwanath R. Lingappa, MD, PhD

Co-Chief Executive Officer, Chief Technology Officer and Member of the Board of Directors, Prosetta Biosciences, Inc.

Vishwanath R. Lingappa is the Founder, Chief Technology Officer, and Co-CEO of Prosetta Biosciences, Inc, in San Francisco. In these roles, he is responsible for advancing discovery science of the Prosetta platform and for leading scientific interactions internally and externally. Dr. Lingappa received a B.A. degree from Swarthmore College in 1975, a Ph.D. degree from The Rockefeller University in 1979, and an M.D. degree from Cornell University Medical College in 1980. He completed residency training in Internal Medicine before joining the faculty in the Departments of Physiology and Medicine at the University of California, San Francisco (UCSF) in 1982, where he ran an NIH-funded basic research laboratory for over 20 years. It was during this time that the core discoveries on which Prosetta’s science is based were made and refined in his laboratory. At UCSF, he was heavily involved in medical student and resident teaching and training, and was author and co-editor of highly acclaimed textbooks in physiology, pathophysiology, and cell biology. He has supervised some 40 pre- and post-doctoral trainees, 8 of whom received the Ph.D. degree under his guidance. He has co-authored over 90 publications. He was promoted to Professor in 1991. Dr. Lingappa also practiced internal medicine at San Francisco General Hospital for over 26 years. He maintains voluntary positions as Senior Scientist at the Research Institute of California Pacific Medical Center and Emeritus Professor of Physiology at UCSF. He is recipient of a Kaiser Award for excellence in teaching (1990) and is a Fellow of the American Association for the Advancement of Science (2004).

 

Joseph (Mike) McCune, MD, PhD

Co-Chief Executive Officer and Member of the Board of Directors, Prosetta Biosciences, Inc.

Joseph (Mike) McCune is the Co-CEO of Prosetta Biosciences, Inc. In this role, he is responsible for guiding lead scientific programs into the clinic, and for related aspects of business and drug development. Dr. McCune received a B.A. degree from Harvard College in 1975, an M.D. from Cornell University Medical College in 1982, and, working side-by-side with Dr. Lingappa, a Ph.D. from The Rockefeller University in 1982. After completing residency training in Internal Medicine at UCSF, he carried out post-doctoral research at Stanford, inventing the first generation of “humanized mice.” On the basis of this platform technology, he co-founded SyStemix in 1988, focusing it on the discovery and development of multilineage human hematopoietic stem cells (HSC). After SyStemix went public in 1991, Dr. McCune founded a joint venture between SyStemix and Sandoz, called Progenesys, to develop HSC-based gene therapy approaches against HIV. In 1995, he returned to UCSF to establish collaborative, multidisciplinary teams focused on HIV disease treatment and cure, setting up the Macy’s Center for Creative Therapies (1995), serving as the Director of the UCSF Clinical and Translational Science Institute (2005), and founding and acting as Chief of the Division of Experimental Medicine (1996). He has over 220 publications, and 20 patents issued or pending. He has been a practicing physician at the San Francisco General Hospital AIDS clinic for the past 24 years. He is also a member of many scientific and professional societies, including the American Society for Clinical Investigation, the American Association of Physicians, and the Henry Kunkel Society. On the basis of this work, he was awarded the Elizabeth Glaser Pediatric AIDS Foundation Scientist Award in 1996, the Burroughs Wellcome Fund Clinical Scientist Award in Translational Research in 2000, a MERIT Award from the NIH in 2001, the NIH Director’s Pioneer Award in 2004, the Holly Smith Award for Exceptional Service to the University in 2016, and a number of mentoring awards.